mn-001
mn-001: developed by 1 company · 2 clinical trials tracked.
mn-001 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could mn-001 → MNOV affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| MEDICINOVA INC (MNOV) Diabetes Mellitus, Type 2; Idiopathic Pulmonary Fibrosis | Phase 2 |
Clinical Trials (2)
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MN-001 in Patients Diagnosed With Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Primary endpoint: Mean change in controlled attenuation parameter (CAP) score by sound-based elastography at Week 24
A Randomized, Placebo-Controlled, Double-Blind Six Month Study Followed by an Open-Label Extension Phase to Evaluate the Efficacy, Safety and Tolerability of MN-001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Primary endpoint: Absolute Change From Baseline in Forced Vital Capacity for 26 Weeks
Frequently asked questions
Who is developing mn-001?
mn-001 is being developed by MEDICINOVA INC.
How many clinical trials involve mn-001?
BioSniper tracks 2 clinical trials involving mn-001.